5-bromo-7-methylbenzo[d]oxazol-2(3H)-one | 1268153-81-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并恶唑类
• 英文名称: 5-bromo-7-methylbenzo[d]oxazol-2(3H)-one
• 英文别名: 5-Bromo-7-methyl-2,3-dihydro-1,3-benzoxazol-2-one；5-bromo-7-methyl-3H-1,3-benzoxazol-2-one
• CAS: 1268153-81-6
• 化学式: C₈H₆BrNO₂
• 分子量: 228.045
• InChiKey: VARQARLDHMGBSN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  12
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  38.3
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• SUBSTITUTED HETEROCYCLIC COMPOUNDS AS CRAC MODULATORS
  申请人：LUPIN LIMITED

  公开号：US20160145268A1

  公开（公告）日：2016-05-26

  The invention relates to compounds of Formula (I) and their pharmaceutically acceptable salts, wherein the substituents are as described herein, and their use in medicine for the treatment of diseases, disorders associated with the modulation of calcium release-activated calcium (CRAC) channel. The invention also relates to pharmaceutical compositions containing such compounds in treating diseases disorders associated with calcium release-activated calcium (CRAC) channel modulators. wherein, ring D is Formula (a) or Formula (b): A and B, which may be same or different, are independently CR 3 or N; Y is CR 3 or N; L is selected from —NR 2 C(O)—, —C(O)NR 2 — and —NR 2 CR a R b —; R a and R b are independently hydrogen, halogen or substituted or unsubstituted alkyl; ring E is selected from the Formula (i) to (vii).

  该发明涉及式(I)的化合物及其药用可接受盐，其中取代基如本文所述，并且它们在医学上用于治疗与钙释放激活钙（CRAC）通道调节相关的疾病和紊乱。该发明还涉及含有这种化合物的药物组合物，用于治疗与钙释放激活钙（CRAC）通道调节剂相关的疾病和紊乱。其中，环D是式(a)或式(b)：A和B，可以相同也可以不同，分别独立地为CR3或N；Y为CR3或N；L选自—NR2C(O)—、—C(O)NR2—和—NR2CRaRb—；Ra和Rb独立地为氢、卤素或取代或未取代的烷基；环E选自式(i)至式(vii)。
• Substituted bicycle heterocyclic derivatives useful as ROMK channel inhibitors
  申请人：BRISTOL-MYERS SQUIBB COMPANY

  公开号：US10723723B2

  公开（公告）日：2020-07-28

  Disclosed are compounds of Formula (I) or a salt thereof, wherein R1 is (II) or (III); each W is independently NR1b or O; Z is a bond or CHR1d; and R1, R2, Rd, R3, L1, L2, R1a, R1b, R1c, and n are define herein. Also disclosed are methods of using such compounds as inhibitors of ROMK, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating cardiovascular diseases.

  公开了式(I)化合物或其盐，其中R1是(II)或(III)；每个W独立地是NR1b或O；Z是键或CHR1d；R1、R2、Rd、R3、L1、L2、R1a、R1b、R1c和n在此定义。还公开了使用此类化合物作为 ROMK 抑制剂的方法，以及包含此类化合物的药物组合物。这些化合物可用于治疗心血管疾病。
• SUBSTITUTED BICYCLE HETEROCYCLIC DERIVATIVES USEFUL AS ROMK CHANNEL INHIBITORS
  申请人：Bristol-Myers Squibb Company

  公开号：EP3535258A1

  公开（公告）日：2019-09-11
• SUBSTITUTED BICYCLE HETEROCYCLIC DERIVATIVES USEFUL AS ROMK CHANNEL INHIBITORS
  申请人：Bristol-Myers Squibb Company

  公开号：EP3535258B1

  公开（公告）日：2021-11-24
• SUBSTITUTED NITROGEN CONTAINING COMPOUNDS
  申请人：Bristol-Myers Squibb Company

  公开号：EP3630752B1

  公开（公告）日：2021-06-30